Abstract 20007: Effects of Eicosapentaenoic Acid, Docosahexaenoic Acid, and Olive Oil on Cardiovascular Disease Risk Factors
The effects of eicosapentaenoic acid (EPA) 600 and 1800 mg/day and docosahexaenoic acid (DHA) 600 mg/day versus olive oil placebo on cardiovascular disease (CVD) risk factors were examined over a 6 week period in a randomized, blinded fashion in 110 subjects. All capsules were well tolerated. No significant effects on body weight, systolic blood pressure, pulse, fasting glucose, or fasting insulin levels were noted versus baseline in any group. No significant effects of any supplement on the complete blood count, prothrombin time, liver, kidney, or thyroid function tests, or electrolytes were observed. There were no significant effects on lipids, apolipoproteins, or inflammatory markers observed versus baseline for the low EPA group (n=27), while in the high EPA group (n=29), there were significant (p<0.05) reductions of 16% in fibrinogen, 12% in cholesterol in triglyceride-rich lipoproteins (TRL), 7% for small dense LDL cholesterol, and 6% for lipoprotein associated phospholipase A2 (LpPLA2) and a 16% increase in preβ-1. In the DHA group (n=28), there were significant increases in low density lipoprotein (LDL) cholesterol in both the fasting and fed state of 14.2% and 16.3%, respectively. Also in the DHA group there were significant reductions in fed triglyceride levels of 9.5%. No significant effects on adiponectin, C reactive protein, interleukin-6, tumor necrosis factor alpha, or adhesion molecules were noted for any intervention. The overall data indicate that the beneficial effects of high dose EPA on CVD risk reduction could be related to decreases in LpPLA2, fibrinogen, small dense LDL cholesterol, and in the cholesterol level in triglyceride-rich lipoproteins, as well as increases in very small precursor pre-beta 1 migrating high density lipoproteins. (Supported by contracts and grants from DuPont, NIH, and USDA)
- © 2010 by American Heart Association, Inc.